Fiche publication
Date publication
janvier 2019
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr FUMET Jean-David
Tous les auteurs :
Ghiringhelli F, Fumet JD
Lien Pubmed
Résumé
Immunotherapy using checkpoint inhibitor targeting PD-1 and PD-L1 revolutionized the treatment of microsatellite instable metastatic colon cancer. Such treatment is now a standard of care for these patients. However, when used as monotherapy checkpoint inhibitors targeting PD-1 and PD-L1 are not effective in metastatic colorectal cancer patients with microsatellite stable tumors. Recent advances in biology provide a rationale for this intrinsic resistance and support the evaluation of combination therapy to reverse resistance. This article will highlight recent findings on the mechanism of intrinsic resistance and recent advances in clinical trials for combination therapy.
Mots clés
PD-1, PD-L1, checkpoint inhibitor, colorectal cancer, combination therapy, mismatch repair deficiency
Référence
Front Immunol. 2019 ;10:1816
